FLAVIO JOTA DE PAULA
Índice h a partir de 2011
13
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
conferenceObject Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?(2019) PAIXAO, J. O.; ULISSES, L. R.; SOUZA, P. S.; BEZERRA, G.; AGENA, F.; RODRGUES, H. P.; PANAJOTOPOULOS, N.; PAULA, F. J.; DAVID-NETO, E.; CASTRO, M. R.- Prioritization Due to Dialysis Access Failure Impacts on Patient Survival after Kidney Transplantation(2013) REUSING JR., J.; SOUZA, P.; GALANTE, N.; AGENA, F.; PAULA, F. de; NAHAS, W.; DAVID-NETO, E.Dialysis vascular access failure, recipient of a non-renal solid organ transplantation and previous kidney donation are current indications of priority allocation (PA) for kidney transplant (KT) at our centre. Mortality among PA patients under dialysis is high and risk factors for long-term patient outcomes after transplantation remain largely elusive. In this study we analyzed a cohort of patients that received KT from Jan/2007 to Dec/2011. Long-term patient survival was compared between PA and non PA recipients transplanted in this period of time and clinical relevant data were analyzed. Data were recorded as of Aug/2012. Results: 948 KT were performed at our institution and 93 (9.8%) were included in our PA program. Most PA patients (n=86) had access failure. The mean follow up time was 32 (0 – 69) months. 5-year patient survival was lower in PA patients (76vs 86%, p=0.001). Twenty (21.5%) PA patients died and all deaths occurred in those with access failure, being 70% of them in the first 3 months. Causes of death were infection in 10 patients, bleeding complications (n=6), uremia (n=1), mesenteric ischemia (n=1) and unspecified shock (n=2). Considering this high mortality rate in the first 3 months after transplantation, we compared patients who died in this period of time (group A) vs. those who survived more than 3 months (group B). Age, gender, previous kidney transplants, sensitization, number of HLA mismatches, pre-transplant DSA, pre-transplant diabetes, induction therapy, DGF, rejection, use of heparin, IVIg and time from inscription in the PA program to transplantation were not statistically different between groups. Among 47 patients who were screened for thrombophilia, 83.3% from group A were positive vs. 31.7% from group B (p=0.01). Infection after transplantation and hemorrhagic complications were more frequent in group A. Groups were not different regarding causes of death. PA patients have a lower survival and this excessive death rate occur in the first three months after transplantation mainly due to infections and bleeding. Thrombophilia is very frequent in PA patients with HR....... for death.
conferenceObject No Impact of One Year of Everolimus, as Compared to MPA, in the Reversal of Left Ventricular Hypertrophy in Elderly Renal Transplant Recipients - Preliminary Data from Then Everold Study(2017) DAVID-NETO, E.; AGENA, F.; FURTADO, M.; RODRIGES, A.; ANDRADE, J.; LEMOS, F.; PAULA, F.conferenceObject Thymoglobulin Induction with Tacrolimus and Everolimus Maintenance Therapy in Elderly Kidney Transplantation Results in Prolonged Lymphocyte Depletion and Do Not Favor Regulatory Profile.(2019) DAVID-NETO, E.; FREITAS, G. Ramos de; FERNANDES, M.; AGENA, F.; LEMOS, F. Brambate Carvalhinho; PAULA, F. Jota de; COELHO, V.; GALANTE, N. ZocolerconferenceObject Graft Survival in Sensitized and Non-Sensitized Patients: Role of the Combination of Donor-Specific Antibodies and Acute Rejection(2016) SOUZA, P.; AGUIRRE, A.; BEZERRA, G.; RODRIGUES, H.; AGENA, F.; DAVID, D.; PAULA, F. de; DAVID-NETO, E.; CASTRO, M.conferenceObject Defining pp65 Enemia and qPCR Cut-Offs for Pre-Emptive Therapy of CMV Disease in Low-Risk, Seropositive Renal Transplanted Recipients(2013) DAVID-NETO, E.; LEMOS, A.; BOAS, L. Vilas; LATIF, A.; AGENA, F.; PAULA, F. Jota de; PIERROTI, L.; LEMOS, F.; NAHAS, W.; CAIAFFA FILHO, H.; PANUTTI, C.CMV disease mostly invasive gastro-intestinal with low viremia occurs in approximately 16% of CMV seropositive renal transplant recipients not receiving Thymoglobuline (ATG). Pre-emptive therapy (PETh) to avoid disease in this group should cover the majority of patients at risk (high Negative Predictive Value – NPV). To define cut-offs for whole blood real-time quantitative PCR (qPCR) and antigenemia (pp65) assays and use PETh for CMV disease we collected blood samples weekly from day 7 to 120 after TX in pts CMV IgG+/ IgG+ donors who did not receive ATG. Results remained blinded. A suspicion of CMV disease required new qPCR/pp65 or biopsy. The highest value of pp65 and qPCR in pts without CMV disease one week before disease were used in ROC curves. As for Nov 2012, 92 pts had completed the collections or developed disease. They were males (54%), caucasians (69%), mean age 45±14y, 61% deceased donors, all under TAC/MPA/ Prednisone. Overall 12 pts (13%) had CMV disease (11 invasive gastro-intestinal/ 1 syndrome), at 64±21 days (31-98), and 80 did not. Of these 80 pts, 45 (56%) presented at least one episode of asymptomatic viremia and cleared it spontaneously (8 (18%) had PCR+/pp65+; 26 (56%) Pp65+/qPCR- and 11 (24%) qPCR+/Pp65-). Among pts with viremia or disease there was a trend for a higher pp65+ cells for disease than for viremia (152±352vs31±131/10 6 cells, p=0.073,) detected earlier for disease than viremia (64±21vs80±25 days, p=0.049). ROC curves (area 0.902±0.036, p=0.0001) revealed that pp65 of 4 cells had 83% sensitivity and 83% specificity to predict CMV disease. Using this cut-off, the NPV was 97%. The CMV copies detected by qPCR was higher for disease than for viremia (46657±50671 vs 5438±16681 copies, p=0.001) but time for detection was similar for both (74±25 vs 59±18 days, p=NS). ROC curve (area 0.903±0.056,p=0.0001) revealed that qPCR=844 copies had 83% sensitivity and 86% specificity to predict disease with the same NPV of 97%. These data indicate that both methods are adequate to detect CMV disease prior to its development in this low-risk population. Blood samples collection should start at day 30 and then weekly until day 120. When these cut-offs are reached, starting pre-emptive therapy would lead untreated only 3% of patients who would develop CMV disease.conferenceObject The Benefit of Kidney Transplantation over the Waitlist Depends on the Patient's Comorbidities.(2019) IZQUIERDO, A. Andrade; REUSING JR., J. V.; ONUSIC, V.; AGENA, F.; LEMOS, F. C.; PAULA, F. de; GERAB, F.; DAVID-NETO, E.conferenceObject Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/ Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow -Up of the nEverOld Trial(2019) DAVID-NETO, E.; AGENA, F.; PAULA, F. J.; GALANTE, N. Z.; DAVID, D. S.; RAMOS, F.; TRIBONI, A. K.; ROMANO, P.; EBNER, P. A.; COELHO, V.; ALTONA, M.; FALCI, R.; PIOVESAN, A.; NAHAS, W. C.conferenceObject Can We Use MDRD or CKD-EPI Equation for Donor Selection?(2015) MOURA, B.; MACHADO, D.; AGENA, F.; PAULA, F.; NAHAS, W.; DAVID-NETO, E.; LEMOS, F.conferenceObject Which Post-Transplant Complications Are More Common in Elderly Renal Recipients?(2016) AGENA, F.; PAULA, F.; REICHERT, B.; NEVES, P.; PIOVESAN, A.; NAHAS, W.; DAVID-NETO, E.